




Annex 1

One of the changes in the **new Annex 1 of the European Pharmacopoeia** concerns the **quality control of primary packaging** (i.e., the first container of the product, such as a vial, syringe, or other) for pharmaceutical products. Previously, this control was only conducted by the primary packaging manufacturer. Now, pharmaceutical product manufacturers must also perform this control upon **receiving the primary packaging**. *For instance, if Aptar produces a syringe piston and conducts quality control at the end of production for each batch. And if Sanofi uses this piston in the syringe for its vaccines then, according to Annex 1, quality control for each batch of syringe pistons upon receipt must now be performed.* Here is a **protocol that we can propose** for this new issue:



THE APPLICATION QUESTIONS

Question n°1 :

*"How should I advise my clients if they want to use the **ScanStation** with **filtration membranes**?"*

Previously, for clients using **filtration membranes** with the **ScanStation**, we used to recommend using black membranes for light colonies and white membranes for dark colonies. Recently, the research department made **improvements in the ScanStation software for colony counting on filtration membranes**. Now, the **ScanStation** is capable of reading filtration membranes very well, including light colonies on white membranes. This enhancement significantly broadens the possibilities for **water analysis**, particularly for **beverage quality analysis**.



Question n°2 :

*"Is it possible to **connect our DiluFlow** to a **media auto-preparator**?"*

We don't have a compatibility list for **DiluFlow** / media auto-preparator. **Each request must be tested on a case-by-case basis** with the **customer support** or **application department**.

